NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8 percent as compared to the second quarter of 2014. Operational results decreased 0.9 percent and the negative impact of currency was 7.9 percent. Domestic sales decreased 2.4 percent while international sales decreased 14.3 percent, reflecting operational growth of 0.5 percent and a negative currency impact of 14.8 percent. For the second quarter, the company posted net earnings of $4.5 billion.

Worldwide, vision care sales in the second quarter dropped to $646 million, down 8.6 percent percent from second quarter results in 2014. U.S. sales in the first quarter totaled $243 million, down 7.3 percent from second quarter 2014. International sales fell 9.4 percent, to $403 million.

“Our solid sales and earnings results in the quarter reflect the strong underlying growth we’re seeing across the enterprise,” said Alex Gorsky, chairman and CEO. “Our diverse portfolio and scale are enabling this performance, and we’ve continued to invest in building a robust enterprise pipeline that will drive our growth over the long term. Our passion to deliver transformational new medicines and products reflects the ongoing commitment of our dedicated employees to improve health and well-being."

Positive contributors to consumer operational results were sales of over-the-counter products including Zyrtec allergy medications and Tylenol analgesics; international feminine protection products; and Listerine oral care products.

Worldwide Pharmaceutical sales of $7.9 billion for the second quarter represented a decrease of 6.6 percent versus the prior year with operational growth of 1.0 percent and a negative impact from currency of 7.6 percent. Domestic sales decreased 1.5 percent; international sales decreased 12.7 percent, which reflected an operational increase of 3.8 percent and a negative currency impact of 16.5 percent.